Periodic Reporting for period 1 - VD-1 (The World’s First Autonomous Blood Drawing Device)
Période du rapport: 2023-06-01 au 2024-03-31
Vitestro has created the first fully-autonomous device that draws blood from patients. Our solution, called VD-1, performs the whole
venipuncture procedure, from vein detection to bandage application, without any human intervention. We have fully developed our
technology in-house and protected it with seven patents. More than 2,500 patients have tried our solution: the user acceptance, first-time
success rate, and hemolysis rate are comparable to those measured using human nurses. The VD-1 will mitigate the chronic shortage
of healthcare personnel. It will also standardize the venipuncture process, which has been substantially unchanged for decades. We target
two categories of customers – lab chains and hospital labs – and we have launching customers in both of them. Vitestro has a team of
over 70 people, including technical, medical, regulatory, and commercial expertise.
venipuncture procedure, from vein detection to bandage application, without any human intervention. We have fully developed our
technology in-house and protected it with seven patents. More than 2,500 patients have tried our solution: the user acceptance, first-time
success rate, and hemolysis rate are comparable to those measured using human nurses. The VD-1 will mitigate the chronic shortage
of healthcare personnel. It will also standardize the venipuncture process, which has been substantially unchanged for decades. We target
two categories of customers – lab chains and hospital labs – and we have launching customers in both of them. Vitestro has a team of
over 70 people, including technical, medical, regulatory, and commercial expertise.
- We kicked off the A.D.O.P.T. Trial, which is the largest trial in autonomous blood drawing worldwide.
- We enrolled the first 1,000 patients in 3 European Hospital Laboratory sites.
- We expect to launch this trial in Q2 also a 4th leading European Hospital Laboratory.
- We have completed the technology objectives, increase safety and performance and preparing the device for industrialization.
- We have solved multiple technical challenges in integration of hardware and software
- We expect to obtain CE-Marking in 2024.
- We enrolled the first 1,000 patients in 3 European Hospital Laboratory sites.
- We expect to launch this trial in Q2 also a 4th leading European Hospital Laboratory.
- We have completed the technology objectives, increase safety and performance and preparing the device for industrialization.
- We have solved multiple technical challenges in integration of hardware and software
- We expect to obtain CE-Marking in 2024.
- We have raised a Series A-1 funding round of €20M with a consortium of multiple EU and U.S. partners, including EIC Fund
- We have presented trial results at Dutch congress NVKC as well as NVML
- We have shared new signings of customers in Denmark and the Netherlands as a press release
- We have grown the team from 50 to 70+ people
- We have participated as a semi-finalist in the ADLM Disruptive Innovation Award
- We have presented trial results at Dutch congress NVKC as well as NVML
- We have shared new signings of customers in Denmark and the Netherlands as a press release
- We have grown the team from 50 to 70+ people
- We have participated as a semi-finalist in the ADLM Disruptive Innovation Award